Eye Drop

Ocuphire Pharma and FamyGen Life Sciences have entered into a global licensing agreement that will allow Famy to fund and commercialize the development of Nyxol eye drops in the U.S. as well as globally, according to a press release.

With a new pharmaceutical treatment option, my conversations with presbyopic patients have gotten a lot more exciting.

The first patient has been dosed in the phase 2 DR:EAM clinical trial assessing OTT166 for the treatment of diabetic retinopathy, according to a press release from OcuTerra Therapeutics.

WASHINGTON — In this Healio Video Perspective from the American Society of Cataract and Refractive Surgery meeting, Marguerite B. McDonald, MD, discusses iVizia, a new dry eye product from Théa Pharma that recently launched in the U.S.

Presbyopia is a ubiquitous and progressive symptom of aging that was previously only treatable with reading glasses, contacts or surgery, but patients now have a new option to help their aging eyes: eye drops.

Vuity is our first FDA-approved pharmaceutical agent labeled for the treatment of a refractive error, presbyopia.

The future for presbyopia is bright no matter what side you are on. For drops, the benefits are that they are nonsurgical and well tolerated, and the risk profile is relatively safe. The con is that for many patients, they will not work.

In this episode, Allisa Song, a medical student and the CEO and co-founder of Nanodropper, discusses the inception of the device, how it can benefit the eye care industry and more.

Nyxol demonstrated positive topline results in subjects with night vision disturbances in the phase 3 LYNX-1 pivotal clinical trial, Ocuphire Pharma announced in a press release.

Putting an eye drop in a young kid’s eye is tough. Putting an eye drop in your own young kid’s eye is impossible.